NPM1 and acute myeloid leukemia: There are already convincing data showing that there is no need to stipulate a blast threshold for AML cases associated with mutations in the carboxy‐terminal insertion mutations in the nucleophosmin‐1 (NPM1), the most common somatic mutations identified in de novo AML.